Inhaled corticosteroids and COVID-19 reply by Maes, Tania et al.
Maes and colleagues (1) fail to point out the inhibitory
in vitro effects of ICS on local and systemic production of IL-6
(5, 6), this being the strongest predictor for impending
respiratory failure in severe coronavirus disease (COVID-19)
(7). Finally, a more specific suppressive effect from ICS on
SARS-CoV-2 replication has been described with ciclesonide
and mometasone furoate but not with budesonide,
beclomethasone, or fluticasone (8).
We believe that, taken together, these observations reinforce
the need for patients with eosinophilic asthma and COPD to
continue receiving their controller therapy containing ICS, as that
will provide optimal disease control and perhaps also confer
protection against viral triggers, perhaps including SARS-CoV-2. n
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Reply to Lipworth et al.
From the Editorialists:
We totally agree with the letter by Lipworth and colleagues in
response to our editorial emphasizing that patients with asthma
need to continue using their inhaled corticosteroid (ICS)-
containing controller therapy during the coronavirus disease
(COVID-19) pandemic, as this provides optimal asthma control
and also confers some protection against viral triggers, perhaps
including severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) (1). They also highlight several interesting papers,
published after the publication of our editorial, which address
two key research questions: 1) are subjects with asthma at
increased risk of COVID-19 infection and related illness? and
2) does ICS use modulate this risk? Because asthma is a very
heterogeneous disease, we hypothesize that asthma phenotypes
and the type of underlying airway and systemic inflammation
need to be taken into account to answer these questions correctly
(see Table 1).
In children with asthma, allergic sensitization and other
type 2 biomarkers (such as fractional exhaled nitric oxide and
epithelial expression of IL-13, which increases the expression of
inducible nitric oxide synthase) were inversely related to ACE2
(angiotensin-converting enzyme 2), the cellular receptor for SARS-
CoV-2 (2). Moreover, in ICS-naive adults with mild allergic
asthma, segmental allergen bronchoprovocation significantly
reduced ACE2 expression in the bronchial epithelium. In
contrast, nonatopic asthma was not associated with reduced
ACE2 expression, which is in line with the findings by Peters
and colleagues (3), demonstrating no difference in ACE2 gene
expression in induced sputum of subjects of the SARP-3 (Severe
Asthma Research Program-3) as compared with healthy control
subjects, as atopy is less prevalent in adults with severe asthma.
In addition, in samples from bronchial brushes and biopsies,
there were similar levels of ACE2 mRNA expression in healthy
volunteers and adult subjects with mild-to-moderate asthma or
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severe asthma (4). Again, an inverse correlation between ACE2
and T-helper cell type 2 cytokine–dependent gene expression
was observed. Indeed, IL-13 treatment of primary airway
epithelial cells significantly reduced ACE2 expression but
increased expression of TMPRSS2 (transmembrane protease
serine 2) (5). Importantly, ACE2 has been identified as an IFN-
stimulated gene in human airway epithelial cells and lung type II
pneumocytes (6). Because IFNs are key mediators of our host
defense against viral infections and because ACE2 is supposed
to provide tissue-specific protection during lung injury, this
implies that SARS-CoV-2 could exploit IFN-driven upregulation
of ACE2 to propagate infection, leading to severe acute
respiratory distress syndrome, respiratory failure, and mortality.
Intriguingly, increased expression of IFN-stimulated genes has
also been demonstrated in samples from airway brushings and
in blood cells of patients with mild or severe type 2–low asthma,
respectively (7). Lastly, elevated levels of systemic IL-6, most
commonly seen in those with concurrent obesity and asthma,
are not only associated with more severe asthma (8) but also
predict the need for mechanical ventilation in severe cases of
COVID-19 (9).
In conclusion, the risk of severe COVID-19 in subjects
with asthma is influenced by multiple factors, including
demographics (age and sex), ethnicity, genetics, treatment
(e.g., ICS treatment), asthma severity, lung function, level of
asthma control, exacerbation frequency, asthma phenotype (type
2–high vs. type 2–low asthma) and comorbidities (see Table 1).
Large-scale epidemiologic studies, clinical trials, and
mechanistic studies are needed to disentangle the relative
importance of these and other risk or protective factors in
modulating the susceptibility of those with asthma to SARS-CoV-2
infection and severe COVID-19. n
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Table 1. Heterogeneity of Asthma and Potential Risk of Severe COVID-19
Characteristic of Subject with
Asthma
No Increased Risk of COVID-19
(or Decreased Risk) Increased Risk of COVID-19
Age Children and adolescents Older subjects
Asthma phenotype Type 2–high asthma Type 2–low asthma
Airway gene expression Type 2 cytokines (e.g., IL-13) IFN-stimulated genes
Systemic inflammation Low IL-6 High IL-6
Comorbidities Allergic sensitization Obesity, diabetes, or hypertension
Asthma severity Mild-to-moderate asthma: GINA steps 1–4 Severe asthma: GINA step 5
Lung function Normal Impaired
Asthma control Well controlled Uncontrolled
Exacerbation frequency No exacerbations Frequent exacerbations
Controller treatment ICS OCS: repetitive bursts or OCS maintenance
treatment
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Fungal Infection during COVID-19: Does Aspergillus
Mean Secondary Invasive Aspergillosis?
To the Editor:
We read with great interest the letter “COVID-19–associated
Pulmonary Aspergillosis” by van Arkel and colleagues (1). The
authors report a high incidence of presumed invasive pulmonary
aspergillosis (6 of 31; 19.4%) among patients with coronavirus
disease (COVID-19) admitted to intensive care.
In light of the recent studies revealing the high incidence of
influenza-associated pulmonary aspergillosis (2), it seems natural to
expect similar complications in severe forms of COVID-19
pneumonia. However, we would like to discuss some particular points.
Among the six patients presented by the authors, two had
chronic obstructive pulmonary disease (COPD), another had
asthma with inhaled corticoid therapy, and a fourth received oral
prednisone. The association between aspergillosis and COPD is well
known; in a recent prospective study, 14% of patients with COPD
exacerbations had respiratory samples with Aspergillus spp. of
unclear clinical significance (3). Corticosteroid therapy is also a
known risk factor for Aspergillus colonization (4). Furthermore,
these four patients had an A. fumigatus–positive culture on a single
respiratory sample, and aspergillosis was diagnosed within 3–5
days after ICU admission. Because no previous negative respiratory
sample was available, the preexisting presence of Aspergillus cannot
be ruled out. Finally, the fifth patient had only a single positive
galactomannan on a BAL.
Eight years ago, Blot and colleagues proposed criteria for defining
invasive aspergillosis in critically ill patients using histopathology-
controlled cases as references (5). For immunocompetent patients,
the direct examination of hyphae in respiratory samples was
mandatory to classify the case as putative, which would have
excluded all the presented cases. Criteria have evolved since then and
are now similar to those suggested by the authors for the diagnosis of
COVID-19–related aspergillosis, that is, Aspergillus spp. cultured
from BAL (without direct examination) or a galactomannan index of
1 or greater on BAL or 0.5 or greater on serum. However, diagnosing
an invasive aspergillosis in an immunocompetent individual solely
on a single positive respiratory specimen culture or a single
galactomannan index might be adventuresome. Indeed, this
generates a risk of artificially increasing the incidence of aspergillosis
and the overuse of antifungal treatments.
To illustrate this point, we present two cases of patients
hospitalized for severe COVID-19 in our institution. Following the
same criteria, secondary invasive aspergillosis would have been
diagnosed in them. Nevertheless, they presented favorable outcomes
without any antifungal treatment, which from our point of view
makes the diagnosis refutable.
The first patient was a 66-year-old immunocompetent man with
type 2 diabetes who was hospitalized for 21 days in our ICU. A BAL
performed on Day 7 was positive for galactomannan (index=3.2).
Antifungal treatment was not administered because the direct
examination, the A. fumigatus PCR, and the culture were negative, as
were the serum galactomannan and b-D-glucan. The patient presented
a favorable outcome and was later discharged from the hospital.
The second patient was a 38-year-old woman with obesity,
hypertension, type 2 diabetes, and rheumatoid arthritis treated
with methotrexate. She required venovenous extracorporeal membrane
oxygenation and was therefore hospitalized in our ICU for 11 days.
Several colonies of A. niger were found on a protected distal respiratory
sample performed on Day 4 but not on later samples. This patient did
not receive any antifungal treatment, but her respiratory state improved
nonetheless.
The diagnosis of invasive aspergillosis is difficult and
based on a body of arguments. This is especially true for
critically ill patients in whom clinical arguments are not
discriminant and computed tomographic scan is either
lacking or difficult to analyze. This is why mycological arguments
play a crucial role in the diagnostic approach. Consequently, we
ask ourselves whether the use of more stringent criteria that are
not limited to a single mycological argument would be preferable.
Also, careful attention should be paid to clearly differentiate
aspergillosis as a subsequent complication of severe COVID-19
pneumonia from aspergillosis in patients with underlying chronic
respiratory diseases (that may be occult noninvasive forms
preexisting COVID-19).
We acknowledge that COVID-19 might be an independent risk
factor for subsequent aspergillosis. It is also possible that underlying
pulmonary conditions may favor COVID-19–associated aspergillosis.
We also fully agree with the authors that classifying aspergillosis
cases is very challenging, especially in the ICU setting. Common
efforts should therefore be made to further assess the pathogenic
nature of the presence of Aspergillus in respiratory samples in ICU
patients with severe COVID-19. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
Arnaud Fekkar, Pharm.D., Ph.D.*








Groupe Hospitalier La Pitié-Salpêtrière
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